LM11A-31: Difference between revisions
Content deleted Content added
No edit summary |
|||
| Line 2: | Line 2: | ||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
[[Category:Experimental drugs for Alzheimer's disease]] |
|||
Revision as of 04:58, 24 May 2024
LM11A-31 is an experimental drug developed for Alzheimer's disease and Huntington's disease.[1][2][3][4][5][6][7][8]
References
- ^ Simmons, Danielle A.; Knowles, Juliet K.; Belichenko, Nadia P.; Banerjee, Gargi; Finkle, Carly; Massa, Stephen M.; Longo, Frank M. (2014-08-25). "A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression". PLoS ONE. 9 (8): e102136. doi:10.1371/journal.pone.0102136. ISSN 1932-6203.
- ^ Elshaer, Sally L.; Alwhaibi, Abdulrahman; Mohamed, Riyaz; Lemtalsi, Tahira; Coucha, Maha; Longo, Frank M.; El-Remessy, Azza B. (2019). "Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway". Diabetologia. 62 (8): 1488–1500. doi:10.1007/s00125-019-4885-2. ISSN 0012-186X. PMC 8808141. PMID 31073629.
- ^ Simmons, Danielle A.; Mills, Brian D.; Butler III, Robert R.; Kuan, Jason; McHugh, Tyne L.M.; Akers, Carolyn; Zhou, James; Syriani, Wassim; Grouban, Maged; Zeineh, Michael; Longo, Frank M. (2021). "Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31". Neurotherapeutics. 18 (2). Elsevier BV: 1039–1063. doi:10.1007/s13311-021-01023-8. ISSN 1878-7479.
- ^ Nasoohi, Sanaz; Tayefeh Ghahremani, Pargol; Alehossein, Parsa; Elyasizadeh, Siyamak; BaniArdalan, Soha; Ismael, Saifudeen; Vatanpour, Hossein; Ahmadiani, Abolhassan; Ishrat, Tauheed (2023). "The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic proNGF". Experimental Neurology. 359. Elsevier BV: 114161. doi:10.1016/j.expneurol.2022.114161. ISSN 0014-4886.
- ^ Simmons, Danielle A; James, Michelle L; Belichenko, Nadia P; Semaan, Sarah; Condon, Christina; Kuan, Jason; Shuhendler, Adam J; Miao, Zheng; Chin, Frederick T; Longo, Frank M (2018-08-15). "TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31". Human Molecular Genetics. 27 (16): 2893–2912. doi:10.1093/hmg/ddy202. ISSN 0964-6906. PMC 6077813. PMID 29860333.
- ^ Nguyen, Thuy-Vi V.; Crumpacker, Rachel H.; Calderon, Kylie E.; Garcia, Frankie G.; Zbesko, Jacob C.; Frye, Jennifer B.; Gonzalez, Selena; Becktel, Danielle A.; Yang, Tao; Tavera-Garcia, Marco A.; Morrison, Helena W.; Schnellmann, Rick G.; Longo, Frank M.; Doyle, Kristian P. (2021-12-10). "Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery". Journal of Pharmacology and Experimental Therapeutics. 380 (2). American Society for Pharmacology & Experimental Therapeutics (ASPET): 126–141. doi:10.1124/jpet.121.000711. ISSN 0022-3565.
- ^ Yin, Guo Nan; Ock, Jiyeon; Limanjaya, Anita; Minh, Nguyen Naht; Hong, Soon-Sun; Yang, Tao; Longo, Frank M.; Ryu, Ji-Kan; Suh, Jun-Kyu (2021). "Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury". The Journal of Sexual Medicine. 18 (1): 17–28. doi:10.1016/j.jsxm.2020.10.015.
- ^ Shanks, Hayley R. C.; Börjesson‐Hanson, Anne; Windisch, Manfred; Massa, Stephen M.; Longo, Frank M.; Schmitz, Taylor W. (December 2022). "Age‐dependent effects of the p75 neurotrophin receptor modulator LM11A‐31 on Alzheimer's disease biomarkers in a 26‐week safety and exploratory endpoint trial". Alzheimer's & Dementia. 18 (S10). doi:10.1002/alz.069079.